EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of Qianlieshutong Capsules in the treatment for Type III prostatitis: A post-marketing, multicenter, randomized, double-blind, single-dummy, active-controlled, parallel-group clinical trial

Huimin Hou, Yuxiao Jiang, Yongming Chen, Fanguo Zhang, Zhengtong Lv, Shengjie Liu, Xiaojin Lu, Haoran Wang, Kai Zhang, Zhigang Ji, Jun Guo, Jinjian Yang und 11 weitere

Phytomedicine · 2026

DOI: 10.1016/j.phymed.2026.158596 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Phytomedicine, 2026. Verfasst von Huimin Hou und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Beijing Hospital, National Center for Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Ge…. Hauptthemen laut MEDLINE: Prostatitis, Drugs, Chinese Herbal, Sulfonamides, Phytotherapy. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS, NIH category III) remains a challenging condition with no universally accepted treatment. Although alpha-blockers and antibiotics are commonly used, their efficacy is inconsistent. PURPOSE: In this study, we aimed to evaluate the efficacy and safety of Qianlieshutong Capsules (QLSTCs, a standardized traditional Chinese medicine) combined with tamsulosin versus tamsulosin alone in patients with CP/CPPS. METHODS: In this post-marketing, multicenter, randomized, double-blind, single-dummy clinical trial, 240 male patients aged 18-50 years diagnosed with CP/CPPS were randomly assigned (1:1) to receive either QLSTCs (0.4 g/capsule, 3 capsules, three times daily) plus tamsulosin (0.2 mg nightly) or a matching placebo plus tamsulosin for 8 weeks. The primary endpoint was the change in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score from baseline to week 8. Secondary outcomes included changes in the NIH-CPSI score at week 4, domain-specific scores (pain, urinary symptoms, quality of life), and treatment response rates. Safety was assessed through adverse events (AEs), laboratory tests, vital signs, and ECG. RESULTS: Of the 240 randomized patients, baseline characteristics were comparable. At week 8, the combination group showed a significantly greater reduction in the total NIH-CPSI score than the control group (14.30 ± 0.53 vs. 10.60 ± 0.54; mean difference = 3.70, 95% CI: 2.36-5.04; P < 0.0001). The effective response rate and marked improvement rate were significantly higher in the combination group. Improvements were also significant in all NIH-CPSI domains at week 8. AE incidences were low and comparable between groups (10.00% vs. 9.24%), with no serious AEs reported. CONCLUSION: The combination of QLSTCs and tamsulosin is a safe and more effective treatment than tamsulosin alone for CP/CPPS, offering superior symptom relief, particularly in pain, urinary symptoms, and quality of life. This approach may serve as a promising multimodal therapeutic option in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstatitisDrugs, Chinese HerbalSulfonamidesPhytotherapyMaleHumansTamsulosinDouble-Blind MethodAdultMiddle AgedYoung AdultAdolescentPelvic PainDrug Therapy, CombinationProduct Surveillance, PostmarketingTreatment OutcomeCapsules

Stichwörter der Autor:innen

Chronic prostatitis/chronic pelvic pain syndromeMulticenter studyQianlieshutong capsulesRandomized controlled trialTraditional Chinese medicine

Substanzen

Drugs, Chinese HerbalTamsulosinSulfonamidesCapsules

Autor:innen und Institutionen

  • Department of Urology, Beijing Hospital, National Center for Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC, Institute of Geriatric Medicine, Chinese Academy of M…
  • Excellence Future International Consulting Co., Ltd, Beijing, China.
  • Medical School, University of Chinese Academy of Sciences, Beijing, China.
  • Department of Urology, Peking University First Hospital, Beijing, China.
  • Department of Urinary Surgery, Peking Union Medical College Hospital, Beijing, China.
  • Department of Andrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.

Zitieren

APA

Hou, H., Jiang, Y., Chen, Y., Zhang, F., Lv, Z., Liu, S., Lu, X., Wang, H., Zhang, K., Ji, Z., Guo, J., Yang, J., Chong, T., Wang, S., Ding, Q., Wang, B., Feng, L., Cui, S., Guo, Y., …, & Wang, J. (2026). Efficacy and safety of Qianlieshutong Capsules in the treatment for Type III prostatitis: A post-marketing, multicenter, randomized, double-blind, single-dummy, active-controlled, parallel-group clinical trial. Phytomedicine. https://doi.org/10.1016/j.phymed.2026.158596

Vancouver

Hou H, Jiang Y, Chen Y, Zhang F, Lv Z, Liu S, et al. Efficacy and safety of Qianlieshutong Capsules in the treatment for Type III prostatitis: A post-marketing, multicenter, randomized, double-blind, single-dummy, active-controlled, parallel-group clinical trial. Phytomedicine. 2026. doi:10.1016/j.phymed.2026.158596

BibTeX
@article{Hou2026,
  author = {Hou, Huimin and Jiang, Yuxiao and Chen, Yongming and Zhang, Fanguo and Lv, Zhengtong and Liu, Shengjie and Lu, Xiaojin and Wang, Haoran and Zhang, Kai and Ji, Zhigang and Guo, Jun and Yang, Jinjian and Chong, Tie and Wang, Shusheng and Ding, Qiang and Wang, Bin and Feng, Liang and Cui, Shu and Guo, Yonglian and Zhang, Haipo and Qin, Zhichuan and Liu, Ming and Wang, Jianye},
  title = {Efficacy and safety of Qianlieshutong Capsules in the treatment for Type III prostatitis: A post-marketing, multicenter, randomized, double-blind, single-dummy, active-controlled, parallel-group clinical trial},
  journal = {Phytomedicine},
  year = {2026},
  doi = {10.1016/j.phymed.2026.158596}
}
Kostenlos starten →